Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (4 quarters reported)
$200M in Q4 2020 → $971M now. Hover for any quarter.
As reported for the quarter ended September 30, 2021. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| BH Bright Health Group Inc | 48.9% | Unchanged | 64,646,937 | $475M |
| Velo3d Inc | 29.4% | New | 37,864,240 | $285M |
| Otonomo Technologies Ltd | 8.6% | New | 19,470,539 | $83.8M |
| Spire Global Inc. | 8.4% | New | 7,277,945 | $82.1M |
| Kymera Therapeutics Inc | 3.7% | Trimmed 50% | 615,895 | $36.2M |
| Tscan Therapeutics Inc | 1.0% | New | 1,245,505 | $9.35M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 3 quarters.
quarter ended September 30, 2021 · filed November 15, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Velo3d Inc | New | +37,864,240 | +$285M | 29.4% |
| Otonomo Technologies Ltd | New | +19,470,539 | +$83.8M | 8.6% |
| Spire Global Inc. | New | +7,277,945 | +$82.1M | 8.4% |
| Ncino Inc | Exited | −781,250 | −$46.8M | — |
| Kymera Therapeutics Inc | Trimmed | −619,413 | −$36.4M | 3.7% |
| Tscan Therapeutics Inc | New | +1,245,505 | +$9.35M | 1.0% |
quarter ended June 30, 2021 · filed November 24, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| BH Bright Health Group Inc | New | +64,646,937 | +$998M | 90.3% |
| Kymera Therapeutics Inc | Trimmed | −425,163 | −$20.6M | 5.4% |
quarter ended March 31, 2021 · filed May 14, 2021
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Ncino Inc | Trimmed | −781,250 | −$52.1M | 44.7% |
| Kymera Therapeutics Inc | Trimmed | −94,885 | −$3.69M | 55.3% |
| Draftkings Inc | Exited | −5,463 | −$254K | — |
Loading...
